In8bio, Inc. (INAB)
NASDAQ:INAB
Want to see INAB full AI Analyst Report?
INAB Stock Chart & Stats
$1.44
-$0.04(-11.59%)
At close: 4:00 PM EST
$1.44
-$0.04(-11.59%)
Day’s Range― - ―
52-Week Range$1.17 - $2.73
Previous CloseN/A
Volume363.43K
Average Volume (3M)62.17K
Market Cap
$14.08M
Enterprise Value-$12.77M
Total Cash (Recent Filing)$21.94M
Total Debt (Recent Filing)$2.35M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Aug 06, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.76
Shares Outstanding9,847,089
10 Day Avg. Volume37,733
30 Day Avg. Volume62,175
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap-0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit25.55
Enterprise Value/Ebitda0.76
Forecast
1Y Price Target
$5.00Price Target Upside247.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Glioblastoma Clinical DataRobust Phase 1/2 glioblastoma PFS improvement (~97% vs SOC) provides durable proof-of-concept for IN8bio’s γδ T cell approach, supporting regulatory engagement and potential accelerated pathways. Sustained clinical efficacy can materially de-risk late-stage development and future commercialization efforts.
Strengthened Cash Position And Narrowing LossesA $21.9M cash balance plus a narrower quarterly loss indicate improved near-term liquidity and tighter cost control versus prior years. This extends runway to advance IND-enabling work and clinical milestones, reducing immediate financing pressure and supporting execution of multi-program clinical plans.
Low Leverage And Falling Total DebtConservative leverage and materially lower absolute debt limit solvency risk and preserve flexibility for strategic financing or partnerships. A lighter debt burden reduces fixed obligations, enabling management to prioritize R&D investment and clinical development without heavy interest-driven cash drains.
Bears Say
No Commercial Revenue; Sustained Net LossesAs a clinical-stage biotech with no product revenues, IN8bio remains fully dependent on trial success to generate commercial cash flow. Ongoing ~-$19M annual losses mean the company cannot self-fund operations long-term and must convert clinical wins into approved products to achieve durable sustainability.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow (~-$14.5M TTM) necessitates recurrent external financing to support development. Even with improving burn, persistent negative cash generation constrains strategic optionality and increases execution risk if capital markets tighten before key clinical inflection points.
Dependence On Equity Raises / Dilution RiskAdoption of an ATM program signals structural reliance on public equity to fund operations. While ATMs provide timing flexibility, repeated issuances dilute existing shareholders and can limit long-term returns unless capital is translated into definitive clinical/regulatory milestones and eventual revenue generation.
IN8bio News
INAB FAQ
What was In8bio, Inc.’s price range in the past 12 months?
In8bio, Inc. lowest stock price was $1.17 and its highest was $2.73 in the past 12 months.
What is In8bio, Inc.’s market cap?
In8bio, Inc.’s market cap is $14.08M.
When is In8bio, Inc.’s upcoming earnings report date?
In8bio, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 48 days.
How were In8bio, Inc.’s earnings last quarter?
In8bio, Inc. released its earnings results on May 07, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.618 by $0.358.
Is In8bio, Inc. overvalued?
According to Wall Street analysts In8bio, Inc.’s price is currently Undervalued.
Does In8bio, Inc. pay dividends?
In8bio, Inc. does not currently pay dividends.
What is In8bio, Inc.’s EPS estimate?
In8bio, Inc.’s EPS estimate is -0.34.
How many shares outstanding does In8bio, Inc. have?
In8bio, Inc. has 9,847,089 shares outstanding.
What happened to In8bio, Inc.’s price movement after its last earnings report?
In8bio, Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.618. Following the earnings report the stock price went down -1.25%.
Which hedge fund is a major shareholder of In8bio, Inc.?
Currently, no hedge funds are holding shares in INAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
In8bio, Inc.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
INAB Stock 12 Month Forecast
Average Price Target
$5.00
▲(247.22% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
VYNE Therapeutics
―
Aprea Therapeutics
―
Ownership Overview
5.04% Insiders
4.50% Mutual Funds
25.63% Other Institutional Investors
63.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---